跳至主要内容
临床试验/NCT03499106
NCT03499106已完成1 期

An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973

Cyclerion Therapeutics1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2018年4月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
24
试验地点
1
主要终点
Area Under the Plasma Concentration Time Curve of IW-1973 From Time Zero Extrapolated to Infinity (AUC[0-inf])

研究概览

简要总结

The primary objective of the study is to evaluate the effect of itraconazole (a potent cytochrome P450 isoenzyme [CYP]3A inhibitor) on the pharmacokinetics of IW-1973.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject is an ambulatory adult between 18 and 75 years old at the screening visit
  • Subject is in good health and has no clinically significant findings on physical examination
  • Body mass index is > 18 and < 30.0 kg/m2 at the screening visit
  • Women of reproductive potential must have a negative pregnancy test at the time of check-in and must agree to use protocol-specified contraception throughout the duration of the study and for 2 months after the final dose of study drug
  • Men must agree to use protocol-specified contraception and also to not donate sperm throughout the study and for 2 months after the final dose of study drug
  • Other inclusion criteria per protocol

排除标准

  • Any active or unstable clinically significant medical condition
  • Use of any prescribed or non-prescribed medication
  • Other exclusion criteria per protocol

研究组 & 干预措施

Healthy Volunteers

Experimental

Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.

干预措施: IW-1973 (Drug)

Healthy Volunteers

Experimental

Period 1: Single dose of IW-1973. Period 2: ITZ is dosed once daily (QD) for 17 days; a single dose of IW-1973 is administered 1 hour after the fourth ITZ QD dose.

干预措施: Itraconazole (Drug)

结局指标

主要结局

Area Under the Plasma Concentration Time Curve of IW-1973 From Time Zero Extrapolated to Infinity (AUC[0-inf])

时间窗: Predose and up to 14 days post dose of IW-1973

Maximum Observed Plasma Concentration (Cmax) of IW-1973

时间窗: Predose and up to 14 days post dose of IW-1973

次要结局

  • Area Under the Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC[0-last]) of IW-1973(Predose and up to 14 days post dose of IW-1973)
  • Apparent Terminal Rate Constant (lambda[z]) of IW-1973(Predose and up to 14 days post dose of IW-1973)
  • Apparent Total Plasma Clearance (CL/F) of IW-1973(Predose and up to 14 days post dose of IW-1973)
  • Time to Cmax (Tmax) of IW-1973(Predose and up to 14 days post dose of IW-1973)
  • Area Under the Concentration-Time Curve From Time Zero to 24 hours AUC(0-24) Postdose of IW-1973(Predose and up to 14 days post dose of IW-1973)
  • Apparent Terminal Half-Life (t1/2) of IW-1973(Predose and up to 14 days post dose of IW-1973)
  • Apparent Volume of Distribution (Vz/F) of IW-1973(Predose and up to 14 days post dose of IW-1973)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

A Trial to Evaluate the Effect of Itraconazole... | 临床试验